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Abstract
Both the ubiquitin-proteasome system (UPS) and the lysosomal autophagy system have emerged 
as complementary key players responsible for the turnover of cellular proteins. The regulation of 
protein turnover is critical to cardiomyocytes as post-mitotic cells with very limited regenerative 
capacity. In this focused review, we describe the emerging interface between the UPS and 
autophagy, with E3’s regulating autophagy at two critical points through multiple mechanisms. 
Moreover, we discuss recent insights in how both the UPS and autophagy can alter metabolism at 
various levels, to present new ways to think about therapeutically regulating autophagy in a 
focused manner to optimize disease-specific cardioprotection, without harming the overall 
homeostasis of protein quality control.
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Introduction
There is the growing recognition of the role that protein quality control systems play in the 
maintenance of the heart during health and disease. These include the ubiquitin-proteasome 
system (UPS) responsible for the turnover of many cellular proteins at the molecular level, 
with the complementary lysosomal autophagy system clearing dysfunctional organelles (e.g. 
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mitochondria), damaged macromolecules, and larger aggregate-prone proteins (pre-amyloid 
oligomers)1,2. With a greater understanding of the diverse role that the UPS and autophagy 
play in the heart, we have identified new and novel links with metabolism that build upon 
simpler first constructs. These findings provide additional ways in which cardiac metabolism 
may be regulated therapeutically through the manipulation of specific ubiquitin ligase 
activities, or more broadly in disease context-specific short-term regulation of autophagy.
Why does protein quality control matter?
Mechanisms that regulate protein turnover and prevent protein aggregation either through 
refolding and/or degradation are critical to the heart in ways that differ from most cells in the 
body. This is because the cardiomyocytes, like neurons, are post-mitotic cells with very 
limited regenerative capacity, in contrast to skin or gut epithelial cells3. Evolutionarily, the 
autophagic removal of damaged organelles4,5 and misfolded proteins by the ubiquitin-
proteasome system6 allows maintenance of cardiac function. Recent studies illustrate that 
the regulation of these two systems additionally controls cellular metabolism7–10. As the 
mechanisms that link these two systems with metabolism become clearer, opportunities to 
intervene and protect the heart in disease may become clear.
Metabolism and Autophagy
Due to the high energy demands of the heart, the ability to extract energy (i.e. produce ATP) 
from variable sources is critical. One contributing factor to this may be the limited energy 
reserves available to the heart11. The links between autophagy and metabolism are most 
evident in time of crisis and/or adaptation as seen during mammalian fetal development. For 
example, at birth, the maternal energy source is interrupted12, leaving the newborn heart to 
function without nutrition until milk arrives. The activation of autophagy has been reported 
in the mouse heart within 30 minutes after birth, staying elevated for at least 24 hours13. 
With maternal delivery of nutrition, autophagy is inhibited by the insulin-mediated 
downregulation of protein degradation14.
Autophagy, amino acids, and ATP in starvation
In the adult heart, starvation-induced autophagy can fuel the heart in multiple ways, 
including the degradation of nucleic acids, the breakdown of proteins, and the lysosomal 
digestion of lipids and sugars15. In as little as 12 hours without nutrition, cardiac autophagy 
is upregulated; however, the significance of this metabolic source can best be seen when it is 
blocked16. Blocking autophagic activity has been reported to accelerate cell death and 
reduce cardiac performance while decreasing available amino acids and ATP in the heart16. 
Conversely, stimulating autophagy has been reported to protect against starvation by limiting 
ATP loss and attenuating ER stress17.
Autophagy regulation of glucose and lipid metabolism in the heart
While fatty acid is the substrate utilized most in the adult heart (cardiomyocytes), glucose 
metabolism has important roles in the heart. For example, the fetal heart primarily utilizes 
glucose as a substrate for ATP production. Similarly, during cardiac stress in the adult heart 
the heart shifts its use of fatty acid utilization in favor or more dependence upon glucose11, 
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as is seen in human heart failure18,19, with regulation attributed to inhibition of PPARα 
activity20, HIF-1α, and other transcription factors (discussed in more detail next). In 
parallel, regulation of autophagy by the mammalian target of rapamycin (mTOR) regulates 
autophagy in the failing heart21. During nutrient deprivation, autophagy activity is increased 
by at least two mechanisms, including AMP activated protein kinase (AMPK) mediated 
activation of autophagy-initiating kinase Ulk122 and by upregulation of the hexokinase-II 
enzyme, a glycolytic enzyme that protects against starvation by inhibiting mTORC123. 
Interestingly, impaired lipid degradation by autophagy (a process termed lipophagy) has 
been reported to contribute to the accumulation of toxic lipids24. In the context of high-fat 
diet induced accumulation of lipids, the proper autophagic clearance has proven important in 
attenuating reactive oxygen species25–27. The attenuation of the lipotoxic cardiomyopathy in 
pressure overload-induced heart failure28 similarly demonstrates the importance of 
autophagy in clearing lipids in cardiac stress, a process regulated by oxidized 
phospholipids29.
Autophagy in the heart
Autophagy is a highly conserved protein quality control system that catabolizes misfolded 
and aggregated proteins as well as damaged, worn organelles for recycling and energy 
homeostasis. Autophagosome nucleation begins with the activation of several autophagy-
related gene (ATG) proteins and with the help of VPS34 (class III phosphoinositide 3 kinase 
vacuolar sorting protein 34) and BECLIN1 (Figure 1A). A double-membraned isolation 
membrane elongates and forms around the ubiquitinated substrate of interest (Figure 1B). 
Adaptor proteins, like p62 (also known as sequestosome 1), bind ubiquitin and assist with 
docking substrate cargo inside the phagophore to be degraded. Closing and sealing of the 
membrane completes autophagosome formation (Figure 1C). Finally, lysosome and 
autophagosome fuse to form the autolysosome. Acidic hydrolases from the lysosome 
degrade the contents of the autolysosome (Figure 1D). The resulting molecular components 
(carbohydrates, lipids, amino acids, and nucleic acids) are released to support cellular 
metabolism and homeostasis30–32. Autophagic flux refers to the entire process of autophagy, 
beginning with the formation of an autophagosome around the cargo to be degraded and 
ending with the release of degraded macromolecules into the cytosol33.
Under basal conditions or low stress, autophagy occurs at low levels to maintain 
homeostasis. These low levels of autophagy are critical for cell survival. Cellular 
homeostasis requires a minimal amount of autophagic flux. Inhibiting autophagy disrupts a 
cell’s homeostasis and can lead to cell death30. Alternatively, autophagy responds rapidly to 
stress, particularly nutrient starvation, which elicits a robust enhancement of autophagic flux 
to meet the energy needs of the cell30. Specifically, cardiac autophagy is required for 
metabolic adaptation by providing amino acids, glucose, and lipids, as described above.
Role of Autophagy in Common Heart Diseases
Our understanding of the role of autophagy in cardiac injury has grown tremendously in 
recent years. It’s significance, and context-dependent cardioprotection has recently been 
reviewed in depth (see Schiattarella and Hill, 201634). We briefly summarize the role of 
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Autophagy in ischemic heart disease, pathological cardiac hypertrophy, and chemotherapy-
induced cardiotoxicity.
Ischemic Heart Disease
The number of people living with ischemic heart disease continues to increase; in fact, it was 
the worldwide leading cause of death in 201035. During ischemic heart disease, narrowed 
coronary arteries cause a reduction of blood flow to the heart resulting in ischemia. Injury 
results from both cardiac ischemia and cardiac reperfusion, each triggering stress in distinct 
ways, however cardiac autophagy has been shown to be cardioprotective during both 
phases 36–38. The energy depletion observed during ischemia triggers autophagic 
mechanisms to replenish metabolic substrates and to remove damaged organelles39. Nutrient 
depletion results in the activation of AMPK (via increased AMP resulting from utilization of 
ATP), which then phosphorylates (inactivates) mTOR and thus disinhibits autophagy to 
enhance flux40,41. During reperfusion, restoration of oxygen and nutrients lead to the 
massive production of reactive oxygen species (ROS). As the electron transport chain 
becomes active in the presence of reestablished oxygen, mitochondrial ROS amplification 
results from ROS-induced ROS release42. Damaged proteins and organelles from lipid 
peroxidation-driven ROS enhances autophagy to clear damaged organelles that would 
further increase oxidative stress and cellular dysfunction42.
Interestingly, there have been reports for and against the benefits of autophagy during 
ischemia and reperfusion. Some reports show that enhances in autophagy are 
cardioprotective during ischemia/reperfusion (I/R) and serve to salvage the myocardium43. 
Similarly, chronic ischemia in a porcine model demonstrated an association between 
elevated autophagy and reduced apoptosis44. Yet, other reports show that autophagy and cell 
death correlate and that inhibition of autophagy reduces cell death45,46. Interestingly, work 
by Matsui et al. demonstrates that autophagy may have dual roles and may be protective 
during ischemia but contribute to death during reperfusion40. In this study, mouse hearts 
subjected to ischemia enhanced autophagy in an AMPK-dependent and cardioprotective 
manner, but mouse hearts subjected to I/R showed beclin1-dependent upregulation of 
autophagy that was not beneficial to the heart40. These data are confusing, making 
inferences of the benefits of autophagy during ischemia and reperfusion difficult. The field 
of autophagy research is young and differing results are likely a result of different models, 
mechanisms, and tools used to measure and induce or inhibit autophagy at different times 
during the I/R continuum. At this time, it appears that autophagy may provide differing 
levels of cardioprotection during the ischemia and reperfusion phases: autophagy during I/R 
can afford cardioprotective effects by providing ATP during the ischemia phase and clearing 
ROS-induced damage during reperfusion. The current consensus is that disease, such as 
ischemic heart disease can result in maladaptive autophagy (too much or too little, Figure 
2A) and that this may be directed by differing signaling pathways during ischemia (AMPK-
mediated) and reperfusion (beclin1-mediated). Research should focus on modulating the 
delicate balance of autophagy during the transient nature of this disease aims to harness the 
benefits of autophagy during I/R.
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Autophagy in pathological cardiac hypertrophy
Hypertension, aortic stenosis, and other disease-related stresses induce pathological cardiac 
hypertrophy, which in time progresses to heart failure. Pre-clinical models of pressure 
overload-induced cardiac hypertrophy demonstrate that autophagic flux increases correlate 
with the degree of hypertrophy47. Repression of autophagy accelerated the progression of 
cardiac hypertrophy48, while therapeutic inhibition of autophagy reduced the amount of 
fibrosis seen49. Genetically increasing autophagic flux (e.g. by cardiac-specific increased 
Beclin-1 expression) resulted in an amplified hypertrophy, while decreased autophagy (via 
Beclin1+/−) and inducing pressure-overload induced hypertrophy attenuated heart failure 
progression4. Recent studies have demonstrated the importance of protein acetylation in 
regulating autophagy and shown that inhibiting the additional autophagy induced by 
pressure-overload prevents an acceleration of maladaptive responses and progression to 
heart failure (Figure 2B)47,50.
The role of autophagy in protecting the heart against stress is complex, as illustrated in 
pressure overload-induced cardiac stress. Adaptive responses in the heart require a minimum 
amount of autophagy4, but induction of autophagy above this baseline level can be 
deleterious51. Too little autophagy may infer nutrient stress of failure to clear harmful 
damaged or misfolded proteins and worn organelles. Too much may needlessly catabolize 
proteins and organelles and thus stress the cell. This obviously depends on the situation of 
the cell’s timely environment. Therefore, therapeutics that aim to harness the vast benefits of 
autophagy in the heart must modulate autophagy in a time and disease-specific manner 
(Figure 2C).
Autophagy in chemotherapy-induced cardiotoxicity
A common side effect of chemotherapies is cardiac dysfunction, with doxorubicin being the 
typical offender in patients. Its dose-dependent cardiotoxicity52,53 may be due to DNA 
damage, mitochondrial damage, and the accumulation of ROS. The induction of cardiac 
autophagy occurs when anthracyclines (e.g. doxorubicin) are given54, mediating one 
mechanism of damage associated with inhibiting cardiomyocyte autophagy55.
Therapies targeting cardiac autophagy to promote cardioprotection
The challenge of thinking about Autophagy as a therapeutic target are the dual roles 
autophagy plays in the heart. In ischemia/reperfusion injury, increasing autophagy is 
cardioprotective. In other contexts, increases in autophagy are beneficial in the initial phases 
(e.g. pressure overload), but then become detrimental over time. Additionally, the complete 
inhibition of autophagy is not tolerated well, making the approach to targeting autophagy 
challenging, and may illustrate both our limited understanding of the underlying molecular 
regulation of autophagy and also limitations in our therapeutic options currently targeting 
primarily mTOR.
autophagy Activators
Several drugs act on the autophagy cascade to regulate its activity, with the cornerstone of 
control being on the mTOR complex. Rapamycin, an inhibitor of mTORC1, increases 
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autophagic flux in the heart, as do other mTOR-targeted drugs such as Torin1, which inhibits 
both mTORC1 and mTORC2 to induce autophagy56. As a drug used for years to prevent 
transplant rejection and suppressing smooth muscle proliferation and cell migration (in drug 
eluting devices for angioplasty)57,58, rapamycin may have application to ischemic heart 
disease, although only pre-clinical studies are currently published59(see Table 1).
Increasing autophagy for cardioprotection
Mice subjected to one week of trans-aortic constriction (TAC) to induce pressure overload-
induced hypertrophy, then given rapamycin for one week (2 mg/kg/day) showed suppressed 
cardiac pressure overload-induced cardiac hypertrophy and improved left ventricular 
ejection fraction compared to control mice60. Mouse hearts subjected to left coronary artery 
ligation to simulate I/R injury following rapamycin treatment (0.25 mg/kg ) exhibited 
reduced infarct size and improved left ventricular function61. In a rabbit I/R model (30 min 
coronary ligation, 24 hr reperfusion), suberoylanilide hydroxamic acid (SAHA) treatment 
one day before the procedure or SAHA treatment at the time of reperfusion reduced infarct 
size and partially rescued systolic function62. Mechanistically, SAHA’s induction of 
autophagy in the infarct region was found to mediate these cardioprotective effects in vivo62.
Recent studies investigating the ability of FDA-approved drugs to modulate mTOR-
independent autophagy have identified the K+ATP channel opener minoxidil and the G(i) 
signaling activator clonidine as small molecules that induce autophagy63. These drugs 
revealed an mTOR-independent pathway regulating autophagy, in which cAMP regulates 
IP3 levels63. Other FDA-approved drugs that happen to induce autophagy include statins64, 
the L-type Ca2+ channel blockers verapamil, nicardipine, nimodipine65, the anti-diabetic 
agent metformin66 and the Class III anti-arrhythmic amiodarone67.
To date, four drugs developed as histone deacetylases (HDAC) inhibitors have been 
developed for hematologic cancers (e.g. advanced primary cutaneous T-cell lymphoma68), 
including Vorinostat (aka suberoylanilide hydroxamic acid or SAHA), Romidepsin, 
Panobinostat, and Belinostat69. Pre-clinical studies suggest that atorvastatin reduces 
pathological left ventricular hypertrophy and remodeling and reduce cardiomyocyte size in 
spontaneously hypertensive rats compared wildtype controls due in part to statin-mediated 
increases in autophagy through the Akt/mTOR pathway70. Simvastatin treated I/R hearts 
exhibited reduced infarct size accompanied by increases in autophagy evidenced by 
suppressed mTOR signaling, increased ULK-1, and increased parkin-mediated mitophagy64.
A host of additional therapies has been shown to alter autophagy and protect the heart from 
I/R injury and to reduce infarct size by upregulating autophagy (Table 2), including anti-
microbial agents like sulfaphenazole and chloramphenicol71,72. Statins, metformin, 
resveratrol, minoxidil, clonidine, amiodarone, intermedin similarly demonstrate protection 
in cardiac ischemia-reperfusion injury, diabetic cardiomyopathy, and doxorubicin-induced 
cardiotoxicity, as summarized in Table 2.
Inhibiting autophagy for cardioprotection
In pre-clinical studies, inhibiting autophagy in doxorubicin-induced cardiomyopathy, 
pathological cardiac hypertrophy, ischemia, and in dilated cardiomyopathy is 
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cardioprotective (Table 3). The PI3K inhibitor 3-Methyladenine has a dual role of inhibiting 
class I and class III PI3K, which inhibits autophagy73. In doxorubicin-induced 
cardiomyopathy, 3-methyladenine treatment significantly improved cardiac function and 
reduced myocardial injury74. Preserved cardiac function was attributed to reduced 
autophagy as measured by beclin1 protein expression and formation of autophagic 
vacuoles74. In pressure overload induced pathological hypertrophy, treatment with the 
antifungal antibiotic trichostatin A blunted both autophagy and the development of cardiac 
hypertrophy75. The general anesthetic propofol has been shown to down-regulate autophagy, 
evidenced by reduced LC3-II and beclin1 protein levels as well as increased levels of 
phosphorylated mTOR76. Using propofol to treat myocardial infarction significantly reduced 
infarct size in response to I/R injury76. Lastly, treatment with granulocyte colony-stimulating 
factor (G-CSF) improved cardiac function and remodeling and reduced myocardial fibrosis 
in a hamster model of human dilated cardiomyopathy (UM-X7.1), which may be attributed 
to its ability to reduce autophagy in an Akt-dependent manner77.
As can be seen by these studies, modulating autophagy in a diseased organ is difficult and 
likely to have off-target effects that are likely to be harmful. Additionally, it is important to 
modulate autophagy – not abolish autophagy – since the latter is likely to be toxic to the 
tissue. Furthermore, autophagy is a dynamic system, and its beneficial effects have been 
shown to be time-dependent. For these reasons, it is crucial that therapies are created and 
implemented with these requirements in mind, and it is necessary to target therapies more 
narrowly in the future.
Beyond mTOR phosphorylation: Taking a Mechanistic look at Post-translational Regulation 
of Autophagy by Ubiquitin
Discussion of the regulation of autophagy centers primarily on the global process, with the 
molecular regulation centering on the mTOR signaling pathway. The availability of 
therapeutics that act either directly or indirectly on mTOR has made this focus in 
cardiovascular disease the obvious first choice to move forward as quickly as possible in 
both pre-clinical and clinical trials69. However, the post-translational regulation of 
autophagy by phosphorylation has been described to both inhibit and promote autophagy 
and has been recently reviewed78. Phosphorylation of the ATG subunits, ULK1, BECLIN1, 
and LC3 has been shown to inhibit or promote autophagy, dependent upon which 
phosphorylation site kinases add the phosphate78. Briefly, phosphorylation of Atg13 (via 
PKA/TORC1/Atg1), Atg1 (via PKA/TORC1), Atg9 (via Atg1), the Atg13/ULK1 complex 
(via ULK1, ATG101, mTOR, Akt, PRKAC, AMPK, RB1CC1), Belcin1 (via AKT, EGFR, 
DAPK, ROCK1, ULK1, AMPK), LC3 (via PRKAC), and ATG5 (via MAPK14) have been 
described in yeast and mammalian systems (for more detail, see Xie, et al., 201578). A 
notable number of additional kinases beyond mTOR can be seen on this list, and may 
represent other ways to regulate autophagy as indicated in the previous section. We now turn 
our attention to ubiquitination as another post-translational modification that regulates 
autophagy via post-translational modification.
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The E3 ligases and the UPS
The E1, E2, E3 (ubiquitin ligase), and deubiquitinating enzymes (DUBs) are primary 
components of the ubiquitin-proteasome system (UPS), which bind specific substrates with 
ubiquitin moieties to target their fate. The specificity of the placement of a ubiquitin tag on 
protein substrates comes from the ubiquitin ligases (aka E3), of which there are up to 800+ 
estimated in the human genome79. The UPS is responsible for the turnover of many proteins 
substrates, both during routine protein turnover or during the clearance of damaged/
misfolded protein (see recent reviews80,81 for more detail). In addition to targeting the 
degradation of protein substrates for degradation, ubiquitination commonly regulates critical 
cellular processes in non-degradative ways, such as mono-ubiquitination to alter cellular 
localization or activity8,82 or by modifying activity (e.g. signaling and transcriptional 
activity)83,84. The mechanistic regulation of autophagy by ubiquitination occurs at two 
primary points: 1) At the autophagy machinery itself (i.e. ATG subunits); and 2) Points 
involved in facilitating the recruitment of autophagy adapters (e.g. p62, NBR1, HDAC6, 
Hdp52)85–88. In addition to these specific molecular mechanisms acting at these two points, 
ubiquitination can also regulate autophagy in an indirect manner whereby poly-ubiquitinated 
protein aggregates are taken away by selective autophagy. In neurodegenerative diseases, 
such as Parkinson’s disease or Alzheimer’s disease, poly-ubiquitinated protein aggregates 
and misfolded soluble amyloid precursor proteins recruit autophagy machinery and activate 
the process of selective autophagy89,90.
Direct Regulation of Autophagy by Ubiquitination
Ubiquitin-regulated mTOR activity (via DEPTOR regulation)—The β-TrCP (beta-
transducin repeat-containing protein) ubiquitin ligase (E3) specifically ubiquitinates the 
DEPTOR (DEP-domain-containing mTOR-interacting protein), resulting in the disinhibition 
of mTORC1 (Figure 3A)91,92. β-TrCP apparently recognizes phosphorylated substrates (e.g. 
phosphorylated DEPTOR) and targets them for degradation thereby acting as a negative 
feedback loop to counterbalance kinase activity93. When the HeLa cells (cervical cancer) or 
a glioblastoma cell line (T98G) are serum refed to induce phosphorylation, β-TrCP has been 
reported to mediate the ubiquitin-dependent degradation of DEPTOR94–96. In this way, the 
β-TrCP increases mTOR activity resulting in an inhibition of autophagy (Figure 3A)95,96. 
Multiple studies have identified DEPTOR in cardiomyocytes, implicating p38 activity in its 
regulation97.
Ubiquitin-Regulated BECLIN1 in Nucleation—The ubiquitin ligases TRAF6 (TNF-
receptor-associated factor 6) and NEDD4 (neural precursor cell-expressed developmentally 
downregulated 4) are ubiquitin ligases that have been implicated in regulating autophagy 
nucleation by their regulation of BECLIN1 (Figure 3A). TRAF6 is associated with toll-like 
receptors (TLRs) and the IL-1 receptor in activating NF-kB98,99. Activation of TLR4, IL-1, 
or IFN-gamma induce TRAF6-mediated K63 (non-degradative) poly-ubiquitination to 
inhibit NF-kB activity100. In the context of autophagy, TRAF6 similarly poly-ubiquitinates 
BECLIN1with K63-linked ubiquitination in macrophage101,102. The deubiquitinating 
enzyme (DUB) A20 reported counteracts TRAF6 activity by limiting Beclin1 
ubiquitination102. BECLIN1 interacts with ULK1 in a complex with the AMBRA1 protein 
and TRAF6103. The activation of autophagy induces ULK1 ubiquitination with K63-linked 
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chains, stabilizing the ULK1 complex in a TRAF6-dependent manner103. TRAF6 is 
expressed in the heart, so the TRAF6-mediated alterations in myocardial autophagy may be 
present.
Ubiquitin-Regulated LC3/p62 in Sequestration—The ubiquitin ligase RNF5 (RING 
finger protein 5) is located in the ER and mitochondrial membranes (Figure 3A)104. The 
RNF5 E3 associates with and ubiquitinates the membrane-associated ATG4B protease, an 
enzyme that degrades LC3, to inhibit autophagy (Figure 3A)105. Altering RNF5 expression 
affects LC3 turnover and the formation of the autophagosome, thus controlling autophagic 
flux106. Mice lacking RNF5 (RNF5−/−) exhibit enhanced autophagy-mediated clearance of 
bacteria in macrophage105. RNF5 control of ATG4B is mainly seen under basal autophagy 
conditions, limiting the level of autophagy when not needed106. The RNF5 protein is 
anchored in the ER and has been found in cytoplasmic aggregates in muscle biopsies of 
patients with sporadic inclusion body myositis (sIBM)107. RNF5’s role in cardiac 
autophagy, however, has not been reported.
Like RNF5’s indirect regulation of LC3 levels through its interaction with ATG4B, the 
RNF185 (RING Finger protein 185) regulates p62 by ubiquitinating BNIP1 with its critical 
role in p62 stabilization108. While described as a mitochondrial-localized E3, RNF185 
mediates the non-degradative K63 ubiquitination of BNIP1 (BCL2/adenovirus E1B 19kDa 
interacting protein 1), mediating the recruitment of p62 and LC3 in the formation of the 
autophagosome (Figure 3A)108. The RNF185 mRNA is found in most normal tissues in 
screening assays, including the heart (www.genecards.org), but it’s role in the heart has not 
yet been reported.
The TRIM13 (Tripartite motif-containing protein 13) ubiquitin ligase plays a role in 
regulating ERAD by ubiquitinating MDM2 (mouse double minute 2 homolog) and Akt to 
target their proteasome-dependent degradation109,110. In the presence of ER Stress, TRIM13 
initiates autophagy by interacting with p62 and co-localizing with DFCP1 (double FYVE-
containing protein 1) to regulate autophagosome formation (Figure 3A)111. TRIM13 appears 
to be dispensable in promoting autophagy, so the details on how it regulates p62 are not 
known. The Trim13 mRNA is found in most normal tissues in screening assays, including 
the heart (www.genecards.org).
Another TRIM protein, TRIM5α, is found in the heart and has demonstrated ubiquitin ligase 
activity necessary for the HIV-1 replication112,113. New studies have identified that TRIM5 
directly interacts with p62 and LC3 and play a role in delivering substrates for degradation 
(Figure 3B)114,115. The hypothesis that the TRIM family of proteins may act as pattern 
recognition receptors (PRRs) that may play a general role in autophagy has recently been 
tested114. Of the 6 TRIM proteins tested (TRIM5, TRIM6, TRIM17, TRIM22, TRIM49, and 
TRIM55), all but TRIM55 were in complexes with both ULK1 and BECN1114. TRIM5, 
TRIM6, TRIM7, and TRIM49 all promoted the formation of multimolecular complexes with 
ULK1 and BECN1114. Additional screening studies for siRNA regulating autophagy 
identified that thirty-three (33) TRIM proteins that were involved in autophagy (Figure 3C).
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Ubiquitin ligases with roles in Autophagy Independent of their E3 activity (i.e. 
ubiquitination)—The Cbl (Casitas B-lineage lymphoma) proteins are a highly conserved 
family of ubiquitin ligases that regulate signaling pathways. In the heart, c-Cbl regulates 
focal adhesion protein turnover and myofibril degeneration116. c-Cbl inhibition improves 
cardiac function and survival in ischemia117. Recent studies in squamous cell carcinoma cell 
lines have demonstrated Src is degraded by autophagy, using c-Cbl as a cargo receptor for 
Src (part of the Src-LC3B complex) after the active Src is engulfed in 
autophagosomes118,119. Interestingly, c-Cbl’s role in autophagy appears to be independent of 
its E3 activity; the LIR domain has been found to the be the critical section of c-Cbl 
necessary for the recruitment of Src to the autophagosomes120,121. An image-based genome-
wide siRNA screen revealed that Smurf1 (Smad ubiquitylation regulatory factor-1) is a 
master regulator of viral autophagy and degrades mitochondria (mitophagy) in an E3 activity 
independent manner 122.
Linking Ubiquitin, Autophagy, and Metabolism: Selective Mitophagy
With the essential role of mitochondria in metabolism to produce ATP, the strict monitoring 
of their damage and function is highlighted in studies that demonstrate the loss of cell 
homeostasis with strict monitoring of mitochondrial quality control is dampened123. The 
loss of these quality control systems in multiple types of neurodegenerative diseases, 
including Parkinson’s, appears to be part of the disease pathogenesis. Two autosomal 
recessive forms of Parkinson’s disease results from Parkin and PINK1 mutations123. These 
mutations are essential in the clearance of damaged mitochondria by autophagic pathways in 
a process termed “Mitophagy”. Both Parkin, a ubiquitin ligase, works in concert with 
PINK1, a serine/threonine kinase, to identify and remove damaged mitochondria123.
The Parkin E3 is found primarily in the cytosol124 and regulates mitochondrial autophagy. 
When the PINK1 proteins recognize damaged mitochondria, Parkin ubiquitinates 
mitochondrial proteins such as VDAC1, Mfn1, Mfn2, and Bcl-2 to drive their removal via 
autophagy (Figure 3A)106,125,126. In contrast to Parkin outside of the heart, Parkin-
dependent mitophagy in cardiomyocytes does not appear to play a role in the constitutive 
mitochondrial housekeeping127. Increasing cardiomyocyte Parkin activates mitophagy 
without adverse effects; likewise, deletion of Parkin does not produce a phenotype128,129. 
Instead, the PINK1-Parkin mediated mitophagy plays critical roles in the cardiac stress 
response and has a role in the perinatal transformation of myocardial metabolism127. In 
Parkin−/− mice, normal cardiac function is seen for up to 12 months by 
echocardiography130. However, in response to permanent ligation of the left anterior 
descending (LAD) coronary artery, Parkin−/− mice had a higher mortality at one week (60% 
vs. 20% in the wildtype control mice)130. Of the surviving mice, severe thinning and dilation 
were seen histologically, with significantly greater infarct sizes and decreased function 7 
days after MI, illustrating the important role of Parkin in the adaptive response to MI130. 
Furthermore, overexpression of Parkin in isolated cardiomyocytes protected against 
hypoxia-mediated cell death, suggesting that Parkin plays an important role in the heart’s 
ability to adapt to stress through the removal of damaged mitochondria (mitochondrial 
autophagy, termed mitophagy)131. A separate study showed that ablation of Parkin abolished 
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the cardioprotective effects afforded by ischemic preconditioning, a method of 
cardioprotection that requires enhanced autophagy132.
Muscle-Specific Ubiquitin ligases: Regulation of Cardiac Mass, Metabolism, 
and Autophagy
Muscle-specific E3s regulating cardiac mass: MuRF1, MuRF2, MuRF3, Atrogin-1
The muscle-specific ubiquitin ligases that have been implicated in the turnover of sarcomere 
proteins include the muscle ring finger (MuRF) family proteins and Atrogin-1 (as recently 
reviewed133). The importance of these proteins in protein degradation come from studies of 
both skeletal muscle and cardiac atrophy, whereby MuRF1−/− mice lack the ability to 
degrade some or all of the protein lost in models of atrophy134–137. Subsequent studies have 
additionally demonstrated their roles in regulating cardiac metabolism, including their 
metabolomics profiles at baseline in animal models lacking cardiac MuRF family 
proteins138. Atrogin-1 similarly affects protein degradation when energy metabolism is 
impaired139. Other ubiquitous E3s are found in cardiomyocytes (e.g. CHIP, MDM2, c-Cbl, 
UBE3A/E6AP, cIAP, etc.) and regulate metabolic responses of the heart (e.g. CHIP via 
AMPK chaperone activity)133.
Protein degradation and anaplerosis in striated muscle and heart
The term anaplerosis with respect to the Tricarboxylic acid (TCA) cycle references the 
phenomenon of reactions that contributes to the TCA cycle outside of the linear pathway 
involving citrate synthase. In studies primarily of perfused hearts, the enrichment of TCA 
intermediates to serve as substrates and prevent contractile dysfunction has supported the 
concept of anaplerosis in the heart140,141, but also in skeletal muscle 142. Importantly, the 
TCA intermediates that feed the bypass citrate synthase include the AMINO ACIDS 
ASPARTATE (shuttling to TCA as oxaloacetate) and GLUTAMATE (shuttling to TCA as α-
ketoglutarate).
So when we consider cardiac atrophy as the breakdown and reduction of sarcomere proteins 
by the proteasome (via ubiquitin-dependent manner), the resulting increase in the amino acid 
pool supplies (and specifically ASPARTATE and GLUTAMATE) represents energy that can 
be used to make ATP in place of either glucose or fatty acids143,144. Taken together, the 
ability of muscle-specific E3s to degrade protein to amino acids represents one way in which 
E3s contribute to energy metabolism in their role degrading sarcomere proteins in health and 
disease.
Muscle-specific E3s regulating cardiac metabolism: MuRF1, MuRF2, and MuRF3
Beyond their hypothesized indirect role in anaplerosis, muscle specific ubiquitin ligases have 
been reported to regulate metabolism directly. While beyond the scope of this review, it’s 
worth mentioning that MuRF1 interacts with and regulates creatine kinase in vivo, a critical 
enzyme that shuttles ATP from the mitochondria to the sarcomere M-line10,145. 
Additionally, increasing cardiac MuRF1 results in inhibition of fatty acid oxidation by 
inhibiting PPARα, but not PPARβ/δ or PPARγ1 through a nuclear export mechanism 
involving multi-monoubiquitination around its nuclear export sequence8. Moreover, recent 
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studies have demonstrated that cardiac MuRF1 inhibits thyroid hormone activity in vivo7. 
MuRF1’s interaction with the thyroid receptor alpha and monoubiquitination inhibits thyroid 
hormone activities7, which may impair multiple metabolic processes regulated by thyroid 
hormone in the heart (e.g. fatty acid metabolism)146–148. Complementary to this, cardiac 
MuRF2 and MuRF3 family members attenuate PPARβ/δ and/or PPARγ1 activities to 
protect against PPAR-ligand induced cardiomyopathy seen in high fat diet challenges in 
vivo149,150.
E3s regulating cardiac autophagy: CHIP, Atrogin-1, MuRF1
The ubiquitous Carboxyl terminus of Hsc70 interacting protein (CHIP, encoded by the Stub1 
gene) is an interesting protein with unique roles in protein quality control that include both 
an E3 activity AND a co-chaperone activity, linking misfolded protein recovery (via Hsc70) 
and protein degradation (E3 activity) directly151–153. The role of cardiac CHIP in regulating 
autophagy was demonstrated recently in mice lacking CHIP (CHIP−/−). In a model of 
voluntary running-induced physiological hypertrophy, CHIP−/− mice ran faster and longer 
both before and after training, exhibiting an enhanced cardiac autophagic flux and 
exaggerated physiological (but surprisingly not pathological) cardiac hypertrophy154. While 
the specific mechanism by which autophagy was upregulated is not clear, transcription 
upregulation of autophagy genes (GabarapL1, Atg7, Atg5, Vps34, and Bnip3) was identified 
after five weeks of voluntary running, paralleling increases in autophagic flux154. In vitro 
studies revealed that one mechanism CHIP may be regulating autophagy is through its 
support of Akt signaling to reduce autophagy, whereby CHIP knockdown resulted in and 
inhibited IGF-1 mediated Akt signaling (and presumably enhanced downstream FOXO1/3 
activity) driving increases in the observed autophagic flux154. Recent studies have 
implicated cardiac CHIP in the regulation of AMPK as well155. Given the clear link between 
AMPK and the regulation of autophagy, CHIP may regulate autophagy by multiple 
mechanisms, including its support of AMPK in a ubiquitin ligases-independent manner156, 
linked to AMPK mTOR regulation157.
Recent studies have linked the Atrogin-1 E3 to the regulation of autophagy in the heart. In 
Atrogin1−/− mice, both the UPS and lysosomal system were shown to exhibit reduced 
efficiency with age158. Using a combination of pulsed SILAC (stable isotope labeling of 
amino acids in cell culture) in vivo analyzed by proteomics and biochemical and cellular 
analyses, the charged multivesicular body protein 2B (CHMP2B) was identified as an 
Atrogin-1 substrate158. As part of the endosomal sorting complex (ESCRT) necessary for 
autophagy, mice lacking Atrogin-1 had a buildup of this protein, resulting from failed 
degradation, leading to autophagy impairment, intracellular protein accumulation, which 
then activated the unfolded protein response and cardiomyocyte apoptosis158. Down-
regulation of CHMP2B in Atrogin-1−/− mice restored autophagy and decreased 
proteotoxicity, preventing cell death, and implicating the mechanism that Atrogin-1 
regulates autophagy in vivo. Subsequently, Atrogin1 deletion in zebrafish similarly led to 
impaired autophagy, disruption of the cytoarchitecture in the heart and skeletal muscle, 
leading to a progressive impairment of heart and skeletal muscle159. When human dilated 
cardiomyopathy caused by an Atrogin-1 mutation were studied, they demonstrated evidence 
of severely impaired autophagy and accumulation of the autophagy proteins CHMP2B 
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(mediator of autophagosome-lysosome fusion), beclin1, and LAMP2 (a marker of end-stage 
autophagy)158, consistent with the mechanisms identified in the Atrogin-1 mouse model 
above160. Together these findings suggest a critical role of Atrogin-1 in maintaining 
autophagy and cardiomyocyte health, which has implications in cardiac susceptibility in 
disease and linking the cardiac UPS and autophagy systems for the first time convincingly.
Some of MuRF1 (encoded by the Trim63 gene) and MuRF2 (encoded by the Trim55 gene) 
activities are redundant, evidenced by the spontaneous developmental hypertrophy that 
occurs with deletion of all four MuRF1/MuRF2 and attenuated with the expression of the 
presence of just one allele (of 4) in vivo161. MuRF1 and MuRF2 both interact with titin, 
troponin I and troponin T proteins, and with myosin light chain kinase-2162. And while 
MuRF1−/− and MuRF2−/− hearts have similar metabolomics profiles138, they have 
independent roles in pressure overload-induced cardiac hypertrophy10.
Recent studies have demonstrated that MuRF2’s expression parallels the expression of 
multiple proteins that regulate autophagy, including the proteins nbr1 (an autophagy receptor 
containing LC3- and ubiquitin-binding domains), p62 (a functionally similar autophagy 
receptor to nbr1), and LC3 (a marker of autophagy)163. Additionally, Y2H interaction assays 
have shown that MuRF2 binds the autophagy cargo recognizing adaptor proteins nbr1 and 
p62164, while other studies have shown that the MuRF2A isoform can interact with p62 
while MuRF2B contains a domain for interacting with LC3165. Despite these detailed 
interactions of MuRF2 with the autophagy machinery, its role in regulating autophagic flux 
is not clear. However, recent studies have demonstrated that increasing cardiac MuRF1 
enhances autophagy flux, with MuRF1 deletion significantly inhibiting autophagy166,167. 
The specific molecular targets of MuRF1 have not been validated, but together these suggest 
that MuRF1 and MuRF2 may support autophagy through specific regulation of key 
autophagy steps at the molecular level, which may be utilized in a disease-specific manner to 
modulate autophagic flux and possibly support cardioprotection. However, the therapeutic 
implications of these findings need to be tested directly before any conclusions can be made.
With increasing appreciation of the link between cardiomyocyte energy metabolism and 
protein quality control by the UPS and lysosomal autophagy system, we presented recent 
studies identifying cardioprotection with autophagy is increased (or decreased), depending 
upon the disease-context and duration (Figure 2). We then discussed emerging evidence that 
specific ubiquitin ligases regulate autophagy at two key points, linking the UPS and 
autophagy pathways to each other through multiple mechanisms (Figure 3). In the future, 
targeting these specific mechanisms may allow a more precise and controlled regulation of 
autophagy to promote cardioprotection in a less haphazard way. Therapeutic targeting of 
muscle-specific E3’s, such as Atrogin-1, may be one way to target cardiac autophagy 
specifically, which altering autophagy in metabolically favorable ways through multiple 
mechanisms, as discussed above.
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Non-standard abbreviations
ATG autophagy-related gene
AMPK AMP activated protein kinase
BECN1 Beclin1
b-TrCP beta-transducin repeat-containing protein
Cbl Casitas B-lineage lymphoma
CHIP Carboxyl terminus of Hsc70 interacting protein
CHMP2B charged multivesicular body protein 2B
DEPTOR DEP-domain-containing mTOR-interacting protein
DFCP1 double FYVE-containing protein 1
HDAC histone deacetylases
I/R ischemia/reperfusion
mTOR mammalian target of rapamycin
MuRF1 Muscle Ring Finger-1
NEDD4 neural precursor cell-expressed developmentally
RNF RING finger protein
SILAC stable isotope labeling of amino acids in cell culture
TRAF6 TNF-receptor-associated factor 6
TAC Trans-Aortic Constriction
TRIM Tripartite motif-containing protein
UPS ubiquitin proteasome system
VSP34 vacuolar sorting protein 34
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Highlights
• The ubiquitin-proteasome and lysosomal autophagy systems regulate 
protein degradation
• Protein turnover is particularly critical to post-mitotic cells such as 
cardiomyocytes
• Enhancing or inhibiting autophagy can protect the heart in a disease 
context specific manner
• Ubiquitin ligases regulate autophagy at key points throughout the 
process
• Muscle-specific ubiquitin ligases control autophagy and are potential 
therapeutic targets
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Figure 1. Overview of autophagy regulation and relationship with metabolic adaptation
Autophagy is a protein quality control system that catabolizes misfolded and aggregated 
proteins as well as damaged, worn organelles for recycling and energy homeostasis. Growth 
signaling through IGF-1/Akt/mTOR and high levels of ATP inhibit autophagy. Levels of low 
energy (increased AMP/ATP), high levels of ROS, and misfolded proteins increase 
autophagy through direct activation of VPS34, Beclin1, or ATG proteins, or through the 
disinhibition of mTOR. Autophagosome nucleation begins with the activation of several 
autophagy-related gene (ATG) proteins, with the help of VPS34 and BECLIN1. A double-
membraned isolation membrane elongates and forms around the ubiquitinated substrate of 
interest. Adaptor proteins, like p62 (also known as sequestosome 1), bind ubiquitin and 
interact with LC3-II to assist with docking substrate cargo inside the phagophore to be 
degraded. Closing and sealing of the membrane completes autophagosome formation. 
Finally, lysosome and autophagosome fuse to form the autolysosome. Acidic hydrolases 
from the lysosome degrade the contents of the autolysosome. The resulting molecular 
components (carbohydrates, lipids, amino acids, and nucleic acids) are released to support 
cellular metabolism and homeostasis. INSERT: Basal levels of autophagy are necessary to 
maintain homeostasis. As autophagy increases in response to stress, autophagic flux may 
reach maladaptive levels, assisting in pathological cardiac remodeling. Abbreviations: 
IGF-1, insulin like growth factor-1; PI(3)K, phosphoinositol-2-kinase; Akt, protein kinase A; 
AMP, adenosine monophosphate; ATP, adenosine triphosphate; ROS, reactive oxygen 
species; AMPK, AMP activated kinase; mTOR, mammalian target of rapamycin; ATG, 
autophagy related genes; VPS34, class III phosphoinositide 3 kinase vacuolar sorting protein 
34.
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Figure 2. The role beneficial versus maladaptive role of autophagy during cardiac I/R and 
pressure overload-induced hypertrophy
A) During ischemia, cardiac autophagy is increased in response to low nutrients and oxygen 
in order to provide ATP during “starvation”. During reperfusion, cardiac autophagy may 
decrease in response to the reestablishment of oxygen and nutrients. This reestablishment of 
myocardial blood flow results in increased ROS, leading to lipid peroxidation and damaged 
organelles and proteins. B) During acute cardiac pressure overload, cardiac performance 
decreases. Acute increases in autophagy improve cardiac performance. But over time, with 
chronic pressure overload and chronically increased autophagy, autophagic flux becomes 
maladaptive, assisting in pathological cardiac hypertrophy and remodeling, resulting in a 
decline in cardiac performance and heart failure. C) Basal levels of autophagy are critical to 
maintain cardiomyocyte homeostasis. If autophagic flux drops too low, worn and damaged 
proteins fail to be cleared and cellular functions suffer. If autophagic flux increases too 
much, the cell suffers excessive protein and organelle breakdown. Both cases (too low or too 
high) can lead to cell death and cardiac dysfunction. Adapted from Schiattarella and Hill, 
201630. Abbreviations: LV, left ventricular.
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Figure 3. Over 35 ubiquitin ligases regulate autophagy and fine tune the process by acting at 
three distinct points, based on mechanisms published to date
Our understanding of their specific targets is just beginning, with the A. E3 designation 
noting the E3 substrate targeting the A.1) mTOR, 2) BECLIN1, and 3) P62/LC3 (shown in 
boxes). B. TRIM5 acts as a pattern receongition receptor (PRR) to identify substrates that 
are then cleared by autophagy (e.g. HIV). C. In siRNA screening of regulators of autophagy, 
33 TRIM family proteins were identified that regulate autophagy whose specific molecular 
regulation of autophagy is currently unknown. Panel A: Adapted from Kuang, et al., 
2103106 and Yamano, et al., 2016123. Panels B and C: Data compiled from Kimura et al., 
2016168 and Mandell, et al., 2014169. Public domain mitochondria (Mito) and endoplasmic 
reticulum (ER) from http://www.clker.com/clipart-77218.html and http://www.earth-
site.co.uk/Education/cells-and-cell-structure/#Endoplasmic-Reticulum, respectively. 
(+)=Positive affect on downstream substrate activity; (−) Inhibitory affect on downstream 
substrate activity. NOTE: Net effect is the additive regulation of these (+) and (−) activities 
on the formation of the Early Autophagosome, Phagophore, Autophagosome, and 
Autolysosome. Abbreviations: β-TrCP, beta-transducin repeat-containing protein; MDM2?, 
mouse double minute 2 homolog; RNF5, RING finger protein 5; RNF185, RING finger 
protein 185; SCF complex, Skp, Cullin, F-box containing complex; TRIM5, Tripartite motif-
containing protein 5; TRIM13, Tripartite motif-containing protein 13; TRAF6, TNF receptor 
associated factor 6.
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Table 1
Drugs that induce autophagy by activation of mTOR.
Drug Effect on Autophagy Cardiovascular Therapeutic Action Reference
Rapamycin Activate Suppresses pressure overload-induced cardiac hypertrophy 58
Protects myocardium from I/R injury 59
Improves cardiac function in diabetic mice 61
SAHA* Activate Reduces I/R mediated infarct size 60
*SAHA, suberoylanilide hydroxamic acid
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Table 2
mTOR-independent drugs that induce autophagy and their cardiovascular therapeutic actions.
Drug Effect on Autophagy Cardiovascular Therapeutic Action Reference
Sulfaphenazole Activate Protects myocardium from I/R injury and reduces infarct size 70
Chloramphenicol Activate Attenuates Myocardial I/R injury and reduces infarct size 71
Statins Activate Reduce Infarct size 63
Improves function and reverses pathological remodeling due to hemodynamic stress 69
Metformin Activate Improves cardiac function in diabetic mice 72
Resveratrol Activate Reverses pathological remodeling due to myocardial infarction 73
Protects against doxorubicin-induced cardiotoxicity 74
Improves cardiac function in diabetic mice 75
Minoxidil Activate Vasodilator 62
Clonidine Activate Antihypertensive 62
Amiodarone Activate Class III antiarrhythmic 66
Intermedin Activate Suppresses pressure overload-induced cardiac hypertrophy 76
Biochim Biophys Acta. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Parry and Willis Page 29
Table 3
Drugs that inhibit autophagy and their cardiovascular therapeutic actions.
Drug Effect on Autophagy Cardiovascular Therapeutic Action Reference
3-Methyladenine Inhibit Inhibits doxorubicin-mediated cell death and autophagy, improves cardiac function 77
Trichostatin A Inhibit Reverses pathological remodeling induced by pressure-overload (TAC)# 78
Propofol Inhibit Reduces Infarct size 79
G-CSF* Inhibit Reduces cardiomyocyte death and autophagy in dilated cardiomyopathy model 80
#
TAC, trans-aortic construction
*G-CSF, granulocyte colony-stimulating factor
Biochim Biophys Acta. Author manuscript; available in PMC 2017 December 01.
